AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 191 min read

BTIG reiterates Buy rating on Spyre Therapeutics, $121 price target

BTIG reiterated a Buy rating on Spyre Therapeutics with a $121 price target, implying a 51.4% upside from the Oct 16 close. The firm cited positive Phase 2b data for tulisokibart and a strong pipeline in immune-mediated diseases.

Original reporting
tradingview.com
Published Oct 19, 2026, 5:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG reiterates Buy rating on Spyre Therapeutics, $121 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst's reiteration and raised target could attract new capital and increase trading volume.

02

Market read

A fresh analyst endorsement with a high target may prompt short‑term buying pressure in SPYR.

03

What to watch

Potential competition in IBD space and reimbursement uncertainties.

Relevance 7/10Novelty 6/10Timing: immediate today

Background

Spyre Therapeutics is a clinical‑stage biotech developing long‑acting antibodies for immune‑mediated diseases.

Market effects

Sector

Positive sentiment may spill over to other biotech firms with Phase 2 data.

Regional

Limited to U.S. biotech market.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Target may be overly optimistic given early‑stage data; price could correct if later trials disappoint.

Key entities

  • Analyst Firm
    BTIG

    Equity research firm providing the Buy rating and price target.

  • Company
    Spyre Therapeutics

    Biotech firm developing anti‑TL1A therapies.

Read at source← All news

Related articles

OCT 18
$SYREHighAI 9/10

Spyre presents clinical data on IBD antibody therapies

Spyre Therapeutics (NASDAQ:SYRE) presented clinical data on three IBD antibody therapies (SPY001, SPY002, SPY003) at UEGW 2026, showing proof-of-concept. The SKYLINE study tests these therapies as monotherapies and combinations. Silvio Danese, SKYLINE trial chair, expressed excitement for future combination results.

investing.com2 min
OCT 18
$SYREMed

Mouse studies found combinations of experimental bowel treatments worked better

Spyre Therapeutics (NASDAQ: SYRE) presented preclinical data at UEGW 2026, showing additive efficacy of its IBD antibody combinations (SPY001, SPY002, SPY003) in mouse studies. The company is testing these as monotherapies and combinations in the SKYLINE trial, with clinical proof-of-concept demonstrated across all three antibodies. Spyre aims to raise the therapeutic ceiling for IBD patients with these advanced combination therapies.

stocktitan.net2 min
OCT 16
$SYREMedAI 8/10

Jefferies says this stock remains a top pick among biotech midcaps

Jefferies named Spyre Therapeutics its top pick in small- to mid-cap biotech, citing its pipeline of combination therapies for inflammatory bowel disease. The company's three treatments are expected to report Phase 2 data in 2027. Jefferies highlighted encouraging efficacy signals and favorable safety profiles, with real-world data showing high remission rates.

investing.com2 min
OCT 9
Med

Why is Spyre Therapeutics stock rallying today?

Spyre Therapeutics' stock rose 4.4% in morning trading, recovering from a selldown after a $350M public offering priced at $85 per share. Jefferies highlighted Syros Pharmaceuticals as a top biotech pick for 2027, citing positive data on combination therapies for inflammatory bowel diseases. The broader market also gained, with the S&P 500, Dow Jones, and Nasdaq posting modest increases.

investing.com2 min